On June 15, 2026, CAMP4 Therapeutics Corporation, a biopharmaceutical company traded on Nasdaq under the symbol CAMP, based in Cambridge, Mass., announced the issuance of non-qualified stock options. The Compensation Committee of the Company’s Board of Directors granted a total of 39,000 shares of common stock to three new employees as inducement grants for joining the company. These options are aimed at upregulating gene expression through RNA-targeting therapeutics to restore healthy protein levels, with the objective of treating various genetic diseases. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and signifies the company's focus on expanding its clinical-stage pipeline.